Aberdeen HTA Group (Including: Waugh, Norman, Royle, Pamela, Clar, C., Henderson, Rob, Cummins, E. (Ewen), Hadden, D. R., Lindsay, R. (Robert) and Pearson, Donald). (2010) Screening for hyperglycaemia in pregnancy : a rapid update for the National Screening Committee. Health Technology Assessment, Vol.14 (No.45). pp. 1-183. ISSN 1366-5278

Preview	Text WRAP_Waugh_Screening_hyperglycaemia_pregnancy.pdf - Published Version Download (2251Kb) | Preview
Preview	Text (Coversheet) WRAP_Waugh_Screening_hyperglycaemia_pregnancy_coversheet.pdf - Supplemental Material Download (49Kb) | Preview

Abstract

Background Screening for gestational diabetes has long been a controversial topic. A previous Health Technology Assessment (HTA) report reviewed literature on screening for gestational diabetes mellitus (GDM) and assessed the case for screening against the criteria set by the National Screening Committee. Objective To update a previous HTA report which reviewed the literature on screening for GDM by examining evidence that has emerged since that last report, including the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS), the Maternal and Fetal Medicine Units Network (MFMUN) trial and the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study. To review data on recent trends in maternal age at birth and on the prevalence of overweight and obesity and the effect on prevalence of GDM. Data sources A systematic review and meta-analysis of the literature was carried out. The bibliographic databases used were MEDLINE (1996 to January 2009), EMBASE (1996 to December 2009), the Cochrane Library 2008 issue 4, the Centre for Reviews and Dissemination database and the Web of Science. Review methods For the review of treatment with oral drugs versus insulin, a full systematic review and meta-analysis was carried out. The results of the ACHOIS, MFMUN and HAPO studies were summarised and their implications discussed. Findings of a selection of other recent studies, relevant to the continuum issue, were summarised. Some recent screening studies were reviewed, including a particular focus on studies of screening earlier in pregnancy. Results The HAPO results showed a linear relationship between plasma glucose and adverse outcomes – there is a continuum of risk with no clear threshold which could divide women into those with gestational diabetes and those without. There was good evidence from trials and the meta-analysis that women who fail to control hyperglycaemic in pregnancy on lifestyle measures alone can be safely and effectively be treated with oral agents, metformin or glibenclamide, rather than going directly to insulin. Evidence showed few differences in results between glibenclamide and insulin and metformin and insulin. The exceptions were that there was less maternal hypoglycaemia with glibenclamide, but less neonatal hypoglycaemia and lower birthweight with insulin, and there was less maternal weight gain with metformin. The ACHOIS and MFMUN trials showed reductions in perinatal complications among infants born to mothers who were provided with more intensive dietary advice, blood glucose monitoring and insulin when required. The HAPO study demonstrated adverse outcomes over a much wider range of blood glucose (BG) than the traditional definition of GDM. In the HAPO study, no one measure of BG came out as being clearly the best, although fasting plasma glucose (FPG) was as good as any, and had advantages of being more convenient than an oral glucose tolerance test (OGTT), but correlations between fasting and post-load levels were quite poor. Two screening strategies dominated; (1) selection by the American Diabetes Association criteria followed by the 75-g OGTT [incremental cost-effectiveness ratio (ICER) £3678], and (2) selection by high-risk ethnicity followed by the 75-g OGTT (ICER £21,739). Studies indicated that costs are about £1833 higher for pregnancies complicated by gestational diabetes, suggesting that prevention would be worthwhile. Limitations Not all of the HAPO results have been published, and none of the reviewed economic studies resolved the most difficult issue – at what level of BG does intervention become cost-effective? Conclusions The evidence base has improved since the last HTA review in 2002. There is now good evidence for treatment of oral drugs instead of insulin and it looks increasingly as if FPG could be the test of choice. However some key uncertainties remain to be resolved, which can be done by further analysis of the already collected HAPO data and by using the UK model used in developing the NICE guidelines to assess the cost-effectiveness of intervention in each of the seven HAPO categories.

Item Type:	Journal Article
Subjects:	R Medicine > RG Gynecology and obstetrics
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Diabetes in pregnancy -- Treatment, Medical screening
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	September 2010
Volume:	Vol.14
Number:	No.45
Page Range:	pp. 1-183
Identification Number:	10.3310/hta14450
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes: a national clinical guideline No. 116. 2010. URL: www.sign.ac.uk/guidelines/ fulltext/116/index.html (accessed 5 April 2010). 2. National Institute for Health and Clinical Excellence (NICE). Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period: CG63. 2008. URL: www.nice.org.uk/ Guidance/CG63 (accessed 29 July 2009). 3. Scott DA, Loveman E, McIntyre L, Waugh N. Screening for gestational diabetes: a systematic review and economic evaluation. Health Technol Assess 2002;6(11). 4. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2009. URL: www.screening. nhs.uk/criteria (accessed 7 July 2009). 5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15(7):539–53. 6. Agardh CD, Aberg A, Norden NE. Glucose levels and insulin secretion during a 75 g glucose challenge test in normal pregnancy. J Intern Med 1996;240(5):303–9. 7. Fraser R. Diabetic control in pregnancy and intrauterine growth of the fetus. Br J Obstet Gynaecol 1995;102(4):275–7. 8. Jovanovic L. Third trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth: response to fraser. Diabetes Care 2002;25(6):1104–5. 9. Naylor CD, Sermer M, Chen EL, Sykora K. Cesarean delivery in relation to birthweight and gestational glupcose tolerance – pathophysiology or practice style? JAMA 1996;275(15):1165–70. 10. Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon M. Glycemic control in gestational diabetes mellitus – how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989;161(3):646–53. 11. Agarwal MM, Dhatt GS. Fasting plasma glucose as a screening test for gestational diabetes mellitus. Arch Gynecol Obstet 2007;275(2):81–7. 12. Li DF, Wong VC, O’Hoy KM, Ma HK. Evaluation of the WHO criteria for 75 g oral glucose tolerance test in pregnancy. Br J Obstet Gynaecol 1987;94(9):847–50. 13. Wen SW, Liu S, Kramer MS, Joseph KS, Levitt C, Marcoux S, et al. Impact of prenatal glucose screening on the diagnosis of gestational diabetes and on pregnancy outcomes. Am J Epidemiol 2000;152(11):1009–14. 14. Moses RG, Knights SJ, Lucas EM, Moses M, Russell KG, Coleman KJ, et al. Gestational diabetes: is a higher cesarean section rate inevitable? Diabetes Care 2000;23(1):15–7. 15. Santini DL, Ales KL. The impact of universal screening for gestational glucose intolerance on outcome of pregnancy. Surg Gynecol Obstet 1990;170(5):427–36. 16. Kjos SL, Buchanan TA. Gestational diabetes mellitus. N Engl J Med 1999;341(23):1749–56. 17. Walkinshaw SA. Dietary regulation for ‘gestational diabetes’. Cochrane Database Syst Rev 2000;2:CD000070. 18. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352(24):2477–86. 19. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358(19):1991–2002. 20. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361(14):1339–48. 21. Office for National Statistics. Conception Statistics, England and Wales. 2009. URL: www.statistics.gov.uk/ downloads/theme_population/Table_2.xls (accessed 4 August 2009). 22. ISD Scotland. Births & Babies. 2009. URL: www. isdscotland.org/isd/1436.html (accessed 4 August 2009). 23. Yogev Y, Metzger BE, Hod M. Establishing diagnosis of gestational diabetes mellitus: impact of the hyperglycemia and adverse pregnancy outcome study. Semin Fetal Neonatal Med 2009;14(2):94–100. 24. The NHS Information Centre. Health survey for England 2007: healthly lifestyles: knowledge, attitudes and behaviour. 2008. URL: www.ic.nhs.uk/pubs/ hse07healthylifestyles (accessed 4 August 2009). 25. Heslehurst N, Ells LJ, Simpson H, Batterham A, Wilkinson J, Summerbell CD. Trends in maternal obesity incidence rates, demographic predictors, and health inequalities in 36,821 women over a 15- year period. BJOG 2007;114(2):187–94. 26. Getahun D, Nath C, Ananth CV, Chavez MR, Smulian JC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynaecol 2008;198(5):525. 27. Pedersen J. Weight and length at birth of infants of diabetic mothers. Acta Endocrinologica 1954;16(4):330–42. 28. Metzger BE. Diabetes in Pregnancy Update: 1st Annual Diabetes Symposium of Wisconsin-Milwaukee, 10 May 2008. 2008. URL: www.mcw.edu/FileLibrary/ User/bcozza/Diabetes_in_Pregnancy_Update.pdf (accessed 6 August 2009). 29. HAPO Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynaecol Obstet 2002;78(1):69–77. 30. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28(12):1039–57. 31. American Diabetes Association (ADA). Gestational diabetes mellitus. Diabetes Care 2000;23(Suppl. 1):S77–9. 32. Metzger BE, Coustan DR. Summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus. Diabetes Care 1998;21(Suppl. 2):B161–7. 33. Anon. HAPO results leading to gestational diabetes recommendations. Endocrine Today. December 2008. URL: www.endocrinetoday.com/view. aspx?rid=35571 (accessed 4 August 2009). 34. HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes 2009;58(2):453–9. 35. Lappin TR, Savage GA, Metzger BE, Lowe LP, Haggan SA, Dyer AR. Normative values of hemoglobin A1c (HbA1c) in non-diabetic pregnancy (24–32 wks gestation); data from the hyperglycemia and adverse pregnancy outcome (HAPO) study. Diabetes 2006;55:A217. 36. Ecker JL, Greene MF. Gestational diabetes – setting limits, exploring treatments. N Engl J Med 2008;358(19):2061–3. 37. Lee S, Pettker C, Funai E, Norwitz E, Thung S. Is lowering the diagnostic threshold for gestational diabetes (GDM) cost-effective? Implications from the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Trial. Am J Obstet Gynaecol 2008;199(6):694. 38. Ferrara A, Weiss NS, Hedderson MM, Quesenberry CP Jr, Selby JV, Ergas IJ, et al. Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia. Diabetologia 2007;50(2):298–306. 39. Cheng YW, McLaughlin GB, Esakoff TF, Block-Kurbisch I, Caughey AB. Glucose challenge test: screening threshold for gestational diabetes mellitus and associated outcomes. J Matern Fetal Neonatal Med 2007;20(12):903–8. 40. Dodd JM, Crowther CA, Antoniou G, Baghurst P, Robinson JS. Screening for gestational diabetes: the effect of varying blood glucose definitions in the prediction of adverse maternal and infant health outcomes. Aust N Z J Obstet Gynaecol 2007;47(4):307–12. 41. Di Cianni G, Seghieri G, Lencioni C, Cuccuru I, Anichini R, De BA, et al. Normal glucose tolerance and gestational diabetes mellitus: what is in between? Diabetes Care 2007;30(7):1783–8. 42. Biri A, Korucuoglu U, Ozcan P, Aksakal N, Turan O, Himmetoglu O. Effect of different degrees of glucose intolerance on maternal and perinatal outcomes. J Matern Fetal Neonatal Med 2009;22(6):473–8. 43. Tan PC, Ling LP, Omar SZ. The 50-g glucose challenge test and pregnancy outcome in a multiethnic Asian population at high risk for gestational diabetes. Int J Obstet Gynaecol 2009;105(1):50–5. 44. Jensen DM, Korsholm L, Ovesen P, Beck-Nielsen H, Molsted-Pedersen L, Damm P. Adverse pregnancy outcome in women with mild glucose intolerance: is there a clinically meaningful threshold value for glucose? Acta Obstet Gynecol Scand 2008;87(1):59–62. 45. Hillier TA, Vesco KK, Pedula KL, Beil TL, Whitlock EP, Pettitt DJ. Screening for gestational diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;148(10):766–75. 46. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Screening for gestational diabetes. 2009. URL: www.iqwig.de/s07-01-screeningfor- gestational-diabetes.648.en.html (accessed 4 August 2009). 47. National Institute for Health and Clinical Excellence (NICE). Antenatal care: routine care for the healthy pregnant woman: CG62. 2008. URL: www.nice. org.uk/Guidance/CG62 (accessed 4 August 2009). 48. Reichelt AJ, Spichler ER, Branchtein L, Nucci LB, Franco LJ, Schmidt MI. Fasting plasma glucose is a useful test for the detection of gestational diabetes. Brazilian Study of Gestational Diabetes (EBDG) Working Group. Diabetes Care 1998;21(8):1246–9. 49. Landon MB, Thom E, Spong CY, Carpenter M, Mele L, Johnson F, et al. The National Institute of Child Health and Human Development Maternal- Fetal Medicine Unit Network randomized clinical trial in progress: standard therapy versus no therapy for mild gestational diabetes. Diabetes Care 2007;30(Suppl. 2):S194–6. 50. Landon MB. A prospective multicenter randomized treatment trial of mild gestational diabetes (GDM). Am J Obstet Gynaecol 2008;199(6):S2. 51. Chirayath HH. Diabetes management in pregnancy. Rev Gynaecol Perinat Pract 2006;6(1–2):106–14. 52. Holt RI, Clarke P, Parry EC, Coleman MA. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes Obes Metab 2008;10(10):906–11. 53. Moore TR. Glyburide for the treatment of gestational diabetes: a critical appraisal. Diabetes Care 2007;30(Suppl. 2):S209–13. 54. Moretti ME, Rezvani M, Koren G. Safety of glyburide for gestational diabetes: a metaanalysis of pregnancy outcomes. Ann Pharmacother 2008;42(4):483–90. 55. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 2009;113(1):193–205. 56. Tertti K, Ekblad U, Vahlberg T, Ronnemaa T. Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective, case-control study. Rev Diabet Stud 2008;5(2):95–101. 57. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000;17(7):507–11. 58. Coustan DR. Pharmacological management of gestational diabetes: an overview. Diabetes Care 2007;30(Suppl. 2):S206–S208. 59. Feig DS, Briggs GG, Koren G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Ann Pharmacother 2007;41(7):1174–80. 60. Homko CJ, Reece EA. Insulins and oral hypoglycemic agents in pregnancy. J Matern Fetal Neonatal Med 2006;19(11):679–86. 61. Ramos GA, Jacobson GF, Kirby RS, Ching JY, Field DR. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol 2007;27(5):262–7. 62. Coetzee EJ. Counterpoint: oral hypoglycemic agents should be used to treat diabetic pregnant women. Diabetes Care 2007;30(11):2980–2. 63. Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol 2006;107(6):1303–9. 64. Jovanovic L. Point: oral hypoglycemic agents should not be used to treat diabetic pregnant women. Diabetes Care 2007;30(11):2976–9. 65. Langer O. Management of gestational diabetes: pharmacologic treatment options and glycemic control. Endocrinol Metab Clin North Am 2006;35(1): 53–78. 66. Anjalakshi C, Balaji V, Balaji MS, Seshiah V. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract 2007;76(3):474–5. 67. Bertini AM, Silva JC, Taborda W, Becker F, Lemos Bebber FR, Zucco Viesi JM, et al. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med 2005;33(6):519–23. 68. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343(16):1134–8. 69. Ogunyemi D, Jesse M, Davidson M. Comparison of glyburide versus insulin in management of gestational diabetes mellitus. Endocr Pract 2007;13(4):427–8. 70. Coetzee EJ, Jackson WP. The management of noninsulin- dependent diabetes during pregnancy. Diabetes Res Clin Pract 1986;1(5):281–7. 71. Duncan J, Refuerzo J, Camacho N, Nichanametla J, Blackwell S, Sokol R, et al. The effect of glyburide on pregnancy outcomes in morbidly obese women with gestational diabetes. Am J Obstet Gynaecol 2005;193(Suppl.):289. 72. Fines V, Moore T, Castle S. A comparison of glyburide and insulin treatment in gestational diabetes mellitus on infant birthweight and adiposity. Am J Obstet Gynaecol 2003;189(Suppl.):161. 73. Gilson G, Murphy N. Comparison of oral glyburide with insulin for the management of gestational diabetes mellitus in Alaska native women. Am J Obstet Gynaecol 2002;187(Suppl.):336. 74. Goodman JR, Vavricka B, Spaniol C, Tintera N, Knudtson E, Elimian A. Comparison of glyburide and insulin in the management of gestational diabetes. Obstet Gynecol 2008;111(Suppl.):50S. 75. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005;193(1):118–24. 76. Langer O, Monga S, Most O, Yogev Y, Brustman L. Obese gestational diabetes women: comparison of insulin and glyburide therapies. Am J Obstet Gynecol 2006;195(Suppl.):S436. 77. Patterson TM, Lindsay MK, Duong TH. Glyburide and insulin in the management of A2 gestational diabetes. Obstet Gynecol 2008;111(Suppl.):94S. 78. Yogev Y, Ben-Haroush A, Chen R, Rosenn B, Hod M, Langer O. Undiagnosed asymptomatic hypoglycemia: diet, insulin, and glyburide for gestational diabetic pregnancy. Obstet Gynecol 2004;104(1):88–93. 79. Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol 2004;24(10):617–22. 80. Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med 2004;15(1):51–5. 81. Langer O, Most O, Monga S. Glyburide: predictors of treatment failure in gestational diabetes. Am J Obstet Gynecol 2006;195(Suppl.):435. 82. Parrish MR, Lu G. Predicting glyburide failure in gestational diabetes mellitus. Obstet Gynecol 2008;111(Suppl. 4):46S. 83. Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: Risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol 2006;195(4):1090–4. 84. Velazquez M, Bolnick J, Cloakey D, Gonzalez J, Curet L. The use of glyburide in the management of gestational diabetes. Obstet Gynecol 2003;101(Suppl.):88S. 85. Hague WM, Davoren PM, Oliver J, Rowan J. Contraindications to use of metformin. Metformin may be useful in gestational diabetes. BMJ 2003;326(7392):762. 86. Moore LE, Briery CM, Clokey D, Martin RW, Williford NJ, Bofill JA, et al. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J Reprod Med 2007;52(11):1011–15. 87. Rowan JA. A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial). Diabetes Care 2007;30 (Suppl. 2):S214–S219. 88. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, MiG TI. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358(19):2003–15. 89. Balani J, Hyer S, Rodin A, Shehata H. Pregnancy outcomes in metformin-treated women with gestational diabetes. Diabetologia 2008;51(Suppl. 1):1147. 90. Langer O, Yogev Y, Xenakis EMJ, Rosenn B. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol 2005;192(1):134–9. 91. Ogunyemi DA, Jesse M, Lee G, Ajayi S, Sanchez J. A comparison of glyburide and insulin in management of gestational diabetes mellitus. Obstet Gynecol 2006;107(Suppl.):35S–36S. 92. Nasruddin AB, Clarke P, Coleman MAG, Brown B, Holt RIG. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes Care 2009;24(Suppl. 1):180. 93. National Institute for Health and Clinical Excellence (NICE). The guidelines manual 2009. 2009. URL: www.nice.org.uk/aboutnice/ howwework/developingniceclinicalguidelines/ clinicalguidelinedevelopmentmethods/ GuidelinesManual2009.jsp (accessed 29 July 2009). 94. Cheng Y, Chung J, Block-Kurbisch I, Inturrisi M, Caughey A. Treatment of gestational diabetes mellitus: oral hypoglycemic agents compared to subcutaneous insulin therapy. Am J Obstet Gynecol 2006;195(Suppl. 6):79. 95. Moore L, Clokey D, Robinson A. A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. Am J Obstet Gynecol 2005;193(Suppl. 6):S92. 96. Moore L, Clokey D, Curet L. A randomized controlled trial of metformin and glyburide in gestational diabetes. Am J Obstet Gynecol 2008;199(Suppl. 6):76. 97. Lindsay RS. Many HAPO returns: maternal glycemia and neonatal adiposity: new insights from the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study. Diabetes 2009;58(2):302–3. 98. Agarwal MM, Dhatt GS, Othman Y, Gupta R. Gestational diabetes: fasting capillary glucose as a screening test in a multi-ethnic, high-risk population. Diabetic Medicine 2009;26(8):760–5. 99. Fadl H, Ostlund I, Nilsson K, Hanson U. Fasting capillary glucose as a screening test for gestational diabetes mellitus. BJOG 2006;113(9):1067–71. 100. American Diabetes Association (ADA). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl. 1):S5–20. 101. Agarwal MM, Dhatt GS, Punnose J, Koster G. Gestational diabetes: a reappraisal of HBA1c as a screening test. Acta Obstet Gynecol Scand 2005;84(12):1159–63. 102. Aldasouqi SA, Gossain VV. A proposal for a role of HbA1c in screening for gestational diabetes. Diabet Med 2009;26(8):833–4. 103. Anderberg E, Kallen K, Berntorp K, Frid A, Aberg A. A simplified oral glucose tolerance test in pregnancy: compliance and results. Acta Obstet Gynecol Scand 2007;86(12):1432–6. 104. Ayach W, Costa RA, Calderon IM, Rudge MV. Comparison between 100-g glucose tolerance test and two other screening tests for gestational diabetes: combined fasting glucose with risk factors and 50-g glucose tolerance test. Sao Paulo Med J 2006;124(1):4–9. 105. American College of Obstetrics and Gynecology. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001. Gestational diabetes. Obstet Gynecol 2001;98(3):525–38. 106. Riskin-Mashiah S, Younes G, Damti A, Auslander R. First trimester fasting hyperglycemia and adverse pregnancy outcomes. Diabetes Care 2009;32(9):1639–43. 107. Schaefer-Graf UM, Kjos SL, Kilavuz O, Plagemann A, Brauer M, Dudenhausen JW, et al. Determinants of fetal growth at different periods of pregnancies complicated by gestational diabetes mellitus or impaired glucose tolerance. Diabetes Care 2003;26(1):193–8. 108. Bartha JL, Martinez-Del-Fresno P, Comino- Delgado R. Gestational diabetes mellitus diagnosed during early pregnancy. Am J Obstet Gynecol 2000;182(2):346–50. 109. Most OL, Kim JH, Arslan AA, Klauser C. Maternal and neonatal outcomes in early glucose tolerance testing in an obstetric population in New York city. J Perinat Med 2009;37(2):114–7. 110. Seshiah V, Cynthia A, Balaji V, Balaji MS, Ashalata S, Sheela R, et al. Detection and care of women with gestational diabetes mellitus from early weeks of pregnancy results in birthweight of newborn babies appropriate for gestational age. Diabetes Res Clin Pract 2008;80(2):199–202. 111. Sacks DA, Chen W, Wolde-Tsadik G, Buchanan TA. Fasting plasma glucose test at the first prenatal visit as a screen for gestational diabetes. Obstet Gynecol 2003;101(6):1197–203. 112. Cosson E, Benchimol M, Carbillon L, Pharisien I, Paries J, Valensi P, et al. Universal rather than selective screening for gestational diabetes mellitus may improve fetal outcomes. Diabetes Metab 2006;32:140–6. 113. Masson EA, Lindow SW. Where is the evidence to screen for gestational diabetes? BJOG 2006;113(5):615–16. 114. PSSRU, Compiled by Curtis L. Unit costs of health and social care. 2008. URL: www.pssru.ac.uk/uc/ uc.htm (accessed 6 August 2009). 115. Chen Y, Quick WW, Yang W, Zhang Y, Baldwin A, Moran J, et al. Cost of gestational diabetes mellitus in the United States in 2007. Popul Health Manag 2009;12(3):165–74. 116. Todorova K, Palaveev O, Petkova VB, Stefanova M, Dimitrova Z. A pharmacoeconomical model for choice of a treatment for pregnant women with gestational diabetes. Acta Diabetol 2007;44(3):144–8. 117. Goetzl L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol 2002;22(5):403–6. 118. Lai J, Tan J, Cheng Y, Alexandra G, Liddell J, Caughey A. Cost analysis of metformin vs insulin in management of gestational diabetes. Am J Obstet Gynecol 2008;199(Suppl. 6):818. 119. Kitzmiller JL, Elixhauser A, Carr S, Major CA, de VM, ng-Kilduff L, et al. Assessment of costs and benefits of management of gestational diabetes mellitus. Diabetes Care 1998;21(Suppl. 2):B123–30. 120. Moss JR, Crowther CA, Hiller JE, Willson KJ, Robinson JS, Chipps D, et al. Costs and consequences of treatment for mild gestational diabetes mellitus – evaluation from the ACHOIS randomised trial. BMC Pregnancy Childbirth 2007;7. 121. Lavin JP, Lavin B, O’Donnell N. A comparison of costs associated with screening for gestational diabetes with two-tiered and one-tiered testing protocols. Am J Obstet Gynecol 2001;184(3):363–7. 122. Moses R, Fulwood S, Griffiths R. Gestational diabetes mellitus: resource utilization and costs of diagnosis and treatment. Aust N Z J Obstet Gynaecol 1997;37(2):184–6. 123. Nicholson WK, Fleisher LA, Fox HE, Powe NR. Screening for gestational diabetes mellitus – a decision and cost-effectiveness analysis of four screening strategies. Diabetes Care 2005;28(6): 1482–4. 124. Larijani B, Hossein-nezhad A, Rizvi SW, Munir S, Vassigh AR. Cost analysis of different screening strategies for gestational diabetes mellitus. Endocr Pract 2003;9(6):504–9. 125. Di Cianni G, Volpe L, Casadidio I, Bottone P, Marselli L, Lencioni C, et al. Universal screening and intensive metabolic management of gestational diabetes: cost-effectiveness in Italy. Acta Diabetola 2002;39(2):69–73. 126. Poncet B, Touzet S, Rocher L, Berland M, Orgiazzi J, Colin C. Cost-effectiveness analysis of gestational diabetes mellitus screening in France. Eur J Obstet Gynecol Reprod Biol 2002;103(2):122–9. 127. Thung S, Pettker C, Funai E. Screening for gestational diabetes: is a 130 mg/dl or 140 mg/dl glucose challenge test threshold more cost-effective? Am J Obstet Gynecol 2007;197(6):355. 128. Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF, et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. Obes Rev 2009;10(2):194–203. 129. IADPSG Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33(3):676–82. 130. International Diabetes Federation. Global guideline on pregnancy and diabetes. 2009. URL: www.idf.org/ global-guideline-pregnancy-and-diabetes (accessed 5 April 2010). 131. Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. The antepartum glucose values that predict neonatal macrosomia differ from those that predict postpartum prediabetes or diabetes: implications for the diagnostic criteria for gestational diabetes. J Clin Endocrinol Metab 2009;94(3):840–5. 132. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009;373(9677):1773–9. 133. Simmons D, Rowan J, Reid R, Campbell N. Screening, diagnosis and services for women with gestational diabetes mellitus (GDM) in New Zealand: a technical report from the National GDM Technical Working Party. N Z Med J 2008;121(1270):74–86. 134. Agarwal MM, Dhatt GS, Punnose J, Zayed R. Gestational diabetes: fasting and postprandial glucose as first prenatal screening tests in a highrisk population. J Reprod Med 2007;52(4):299–305. 135. Reece EA, Leguizamon G, Wiznitzer A. Gestational diabetes: the need for a common ground. Lancet 2009;373(9677):1789–97. 136. Massicotte MH, Ardilouze JL, Menard J, Gosselin MJ, Ouellet AB, Moutquin JM, et al. Factors influencing 50-g glucose challenge test results in gestational diabetes. Diabetes 2009;58: A639. 137. Hadden DR, McLaughlin C. Normal and abnormal maternal metabolism during pregnancy. Semin Fetal Neonatal Med 2009;14(2):66–71. 138. Farrar D, Duley L, Lawlor D. Alternative strategies for diagnosing gestational diabetes mellitus to improve maternal and infant health. Cochrane Database Syst Rev 2008;2:CD007122. 139. Tieu J, Crowther C, Middleton P, McPhee A. Screening for gestational diabetes mellitus for improving maternal and infant health. Cochrane Database Syst Rev 2008;3:CD007222. 140. Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol Assess 2007;11(33). 141. Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14(11). 142. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007;11(17). 143. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14(36). 144. Clar C, Barnard K, Cummins E, Royle P, Waugh N. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010;14(12). 145. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88. 146. Khan HA, Sobki SH, Alhomida AS. Fluctuations in fasting blood glucose and serum fructosamine in pregnant women monitored on successive antenatal visits. Clin Exp Med 2006;6(3):134–7.
URI:	http://wrap.warwick.ac.uk/id/eprint/45702

Request changes to a record

Actions (login required)

View Item